PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Pembrolizumab|BIOLOGICAL: PVX-410
Sponsor: Massachusetts General Hospital
Collaborators: Merck Sharp & Dohme LLC